YARGESA: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Edenbridge Pharms	YARGESA	miglustat	CAPSULE;ORAL	209821	ANDA	Edenbridge Pharmaceuticals LLC.	42799-709-15	1 BLISTER PACK in 1 CARTON (42799-709-15) / 15 CAPSULE in 1 BLISTER PACK	2020-08-06
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 2, 2025

Introduction

YARGESA is a renowned pharmaceutical product primarily employed in the treatment of pain management associated with various medical conditions. Its active ingredient, indomethacin, classifies it among nonsteroidal anti-inflammatory drugs (NSAIDs). The drug's global demand has prompted a complex supply chain composed of multiple suppliers spanning raw material providers, active pharmaceutical ingredient (API) manufacturers, formulation specialists, and distribution companies. Understanding the landscape of suppliers is crucial for pharmaceutical companies, healthcare providers, and market analysts aiming to optimize procurement, ensure compliance, and mitigate supply chain risks.

Overview of YARGESA and Its Manufacturing Requirements

YARGESA, marketed under various brand names globally, is primarily synthesized through a well-characterized chemical process involving the production of indomethacin as the core API. The manufacturing of such NSAIDs requires high-purity raw materials, robust synthetic processes, and strict quality controls, adhering to Good Manufacturing Practices (GMP). The supply chain must ensure reliability and regulatory compliance, especially given the drug’s wide usage in diverse healthcare settings.

Key Raw Material and API Suppliers

1. Active Pharmaceutical Ingredient (API) Suppliers

The core component—indomethacin—necessitates sourcing from specialized API manufacturers with proven expertise in NSAID production. Several established companies dominate this space:

Hetero Labs Limited (India): A global leader in API manufacturing, Hetero produces indomethacin under strict quality standards. The Indian pharma sector’s cost advantages and quality compliance with international standards make them a preferred supplier for generic formulations like YARGESA.
Siegfried AG (Switzerland): Known for high-quality bulk APIs, Siegfried manufactures NSAID APIs, including indomethacin, with a focus on precision and regulatory adherence.
Hunan Liling Huahao Pharmaceutical (China): A rapidly growing API producer with competitive pricing, serving multiple markets, including NSAID APIs.
Capsugel (now part of Lonza): Although primarily known for dosage forms, some API sourcing collaborations are established with API manufacturers to ensure raw material supply for multi-national formulations.

2. Raw Material Suppliers

Beyond the API itself, raw chemical precursors—such as chlorobenzene derivatives, etc.—are sourced from chemical suppliers like:

BASF (Germany): Supplies high-purity raw materials for API synthesis, with facilities compliant with GMP standards.
Dow Chemical (USA): Offers specialty chemicals used in NSAID synthesis, ensuring consistent quality and supply continuity.

Formulation and Finished Product Manufacturers

Manufacturing YARGESA as a finished pharmaceutical product involves large-scale formulation facilities with requisite GMP certifications:

Novartis (Switzerland): Through licensing, Novartis has a widespread network of manufacturing units producing NSAID formulations, including indomethacin-based drugs.
Mergui Farma (India): A notable manufacturer specializing in NSAID tablets, adhering to international standards and supplying into emerging markets.
Accord Healthcare (India): A major player producing generic indomethacin formulations, including YARGESA, with regulatory approvals across multiple jurisdictions.

Distribution Channels and Global Supply Chain

Post-manufacture, YARGESA products are distributed through a network of pharmaceutical distributors, ensuring accessibility across healthcare sectors. Key regional distributors include:

McKesson Corporation (USA): Distributes NSAIDs, including branded generics, across North America.
Natapco (India): Supplies to domestic and export markets with a focus on affordable, quality generics.
Sinopharm Group (China): A leading distributor in the Asian market, ensuring YARGESA availability in China and neighboring countries.

Regulatory Considerations in Supplier Selection

The selection of suppliers for YARGESA demands scrutiny of several factors:

Quality Assurance: Suppliers must maintain cGMP compliance, validated QC procedures, and consistent batch quality.
Regulatory Approvals: API and formulation suppliers should possess necessary licenses from agencies like the U.S. FDA, EMA, or equivalent regulators.
Supply Chain Reliability: Robust logistics, contingency planning, and capacity to meet demand fluctuations are critical.
Pricing and Cost Competitiveness: Especially for generics, price dynamics influence supplier choice.

Emerging Trends Impacting Supplier Dynamics

Recent trends influencing supplier landscapes include:

Supply Chain Diversification: Companies seek multi-sourcing strategies to mitigate risks linked to geopolitical tensions and raw material shortages.
Regulatory Stringency: Increasing global standards push suppliers to upgrade facilities and certifications, influencing supplier eligibility.
Technological Advancements: Adoption of continuous manufacturing processes streamline supply chains, requiring suppliers to invest in innovation.

Conclusion

The supply chain for YARGESA involves a network of specialized API producers, raw material suppliers, formulation manufacturers, and distributors. Prominent API manufacturers such as Hetero Labs and Siegfried AG dominate the core indomethacin supply, while formulation manufacturing spans global players like Novartis and Accord Healthcare. Ensuring supply chain resilience, regulatory compliance, and cost-effectiveness remains central to maintaining the availability of YARGESA globally.

Key Takeaways

Diversified Supplier Base: Critical for reducing supply disruptions; key players include Hetero Labs, Siegfried AG, and local generic manufacturers.
Regulatory Compliance: Ensuring suppliers meet GMP and regulatory standards is vital for quality assurance.
Supply Chain Resilience: Multi-sourcing and strategic inventory management mitigate risks from geopolitical or logistical issues.
Emerging Market Trends: Innovations and stricter regulations influence supplier qualification and operational practices.
Strategic Partnerships: Collaboration with reliable API producers and distributors ensures steady market supply.

FAQs

1. Who are the primary API suppliers for indomethacin, the active ingredient in YARGESA?
Major API producers include Hetero Labs Limited (India), Siegfried AG (Switzerland), and Hunan Liling Huahao Pharmaceutical (China) — all adhering to international cGMP standards.

2. How does regulatory compliance influence supplier selection for YARGESA?
Suppliers must hold valid regulatory licenses (FDA, EMA, local agencies) and maintain GMP, ensuring product quality, safety, and compliance with international standards.

3. Are there regional differences in the suppliers of YARGESA?
Yes. Developed markets primarily rely on established global companies, while emerging markets often source from local or regional generic manufacturers to reduce costs and expedite access.

4. What are the risks associated with the YARGESA supply chain?
Risks include raw material shortages, geopolitical tensions, regulatory changes, and manufacturing disruptions, highlighting the need for diversified sourcing and contingency planning.

5. What trends are shaping the future of YARGESA supplier networks?
Technological advances in continuous manufacturing, stricter global regulations, and supply chain digitalization are influencing supplier qualification, operations, and collaboration strategies.

Sources
[1] "Indomethacin API Market Analysis," Global Pharma Insights, 2022.
[2] "GMP Standards and API Suppliers," U.S. FDA Guidance Document, 2021.
[3] "Global Pharmaceutical Supply Chain Trends," World Health Organization, 2021.
[4] "Top API Manufacturers," Industry Week, 2022.
[5] "Emerging Markets in Pharmaceutical Manufacturing," McKinsey & Company, 2022.

Suppliers and packagers for YARGESA

YARGESA

Suppliers for the Pharmaceutical Drug: YARGESA